Human Pheromone Sciences, Inc. - Shareholder Update
28 October 2008 - 5:02AM
PR Newswire (US)
SAN JOSE, Calif., Oct. 27 /PRNewswire-FirstCall/ -- HPSI (OTC:EROX)
(BULLETIN BOARD: EROX) releases letter to its shareholders Dear
Shareholders, In light of events that have shaken the investment
community around the world over the past several weeks, I want to
take this opportunity to update you as to what is happening in your
Company at the present time. Excluding technology advancements, an
update of which will be provided very shortly in another release,
the objectives and strategies for the Company for this year and
2009 are as follows: -- The Company is continuing to work closely
with our current licensees as they undertake programs to introduce
consumer products containing our patented compounds. During this
year we have continued to be closely involved with the J&J
Personal Products Group as they continue product development
efforts under our License Agreement. This project is ongoing and
viable. In mid 2007, we entered into an agreement with Schwarzkopf
and Henkel, for the inclusion of our patented technology in several
of their got2b brand products sold in the United States. During
this year, the Agreement has been expanded geographically to
include Henkel's European businesses and an additional product line
has been included in the Agreement. We continue, this year, to work
with other U.S. and international companies including Avon
Products, who continue to utilize our pheromone compounds. In
addition, we continue to look internationally, and continue to
enter into agreements with companies doing business in Mexico and
Japan. In addition, we are in discussions with several other
companies in the United States and overseas, in efforts to open new
markets for our current technology with local companies, with their
own infrastructures here in this country and in foreign markets.
Not only has our Company benefited financially from our agreements
with these world-class companies, our association with them has
confirmed the viability of our technology, an imperative for a
small technology-based business to generate interest of others in
the longer term. -- While our historical business model has been
validated by these relationships, we are still dependent upon the
internal timetable of these licensees for the generation of
revenues for our Company. However, there are other viable and fast
growing channels in which consumer products are sold, including
electronic media, and direct-to-consumer companies, that may
provide a more consistent flow of revenues to our Company. During
this year, your management has been working to introduce our
technology to several companies who are in leaders in these fields.
We hope to be able to provide more specifics about these efforts
shortly. -- Technology - our heritage, our future; another focus of
our Company. During 2008, we have spent significant amounts of
time, but not a lot of money, in the development of new compounds.
You will be hearing more about the positive results of these
efforts in the next two weeks. -- Merger and Acquisition
Opportunities. We feel strongly that our current technology and new
research and development initiatives can continue to attract
world-class partners. We have also undertaken a program to seek
mergers and/or other types of partnerships that can enhance
shareholder value - our ultimate goal. Unlike many companies whose
share price has dropped radically this year, who have no historic
operations, an un-tested business plan and tens of millions of
shares outstanding, our Company has existing relationships and
agreements with worldwide leaders in the consumer products
industry, is in discussions with other international companies for
the use of our technology, looking to expand our relationships to
provide a more consistent stream of revenues, and has a pipeline of
additional compounds that can offer patented differentiation. And,
importantly, our cash assets exceed our current market valuation,
and we have no interest-bearing debt. Thank you for interest and
support. Please do not hesitate to contact me directly if you have
any questions. Sincerely, William P. Horgan Chairman and CEO
408-938-3030 DATASOURCE: Human Pheromone Sciences, Inc. CONTACT:
William P. Horgan, Chairman and CEO of Human Pheromone Sciences,
Inc., +1-408-938-3030 Web site: http://www.erox.com/
Copyright